Related Experiment Video
Updated: Sep 2, 2025

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma
Chiara Tarantelli1, Francesco Bertoni1,2
1Faculty of Biomedical Sciences, Institute of Oncology Research, Bellinzona, Switzerland.
Abstract:
Polatuzumab vedotin is antibody-drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC. Commentary on: Kawasaki et al. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. Br J Haematol 2022;199:245-255.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

